Sandoz EMA Trastuzumab Application Follows US Filing
European Filing For Herceptin Biosimilar Comes Shortly After FDA Submission
Sandoz and EirGenix have followed their US filing for a biosimilar rival to Herceptin with a European filing for the EG12014 trastuzumab candidate.
You may also be interested in...
Sandoz Lays Out Plan For Rebound With Top Line Stagnant In 2021
Novartis admits that its Sandoz division is not expected to enjoy turnover growth in 2022, due to a lack of material launches, but is planning for a rise in 2023 and beyond.
Novartis Will Not Split Biosimilars From Sandoz As Part Of Review
Reporting Q4 and full-year earnings, Novartis told attendees to the company conference call that evaluating all options for its Sandoz business would take months yet, while making its position clear on Sandoz’ multi-billion-dollar biosimilars business.
EirGenix Makes Progress With Trastuzumab Biosimilar
Taiwan’s EirGenix has made progress with its trastuzumab biosimilar for breast cancer, EG12014, announcing positive Phase III clinical results for the Herceptin equivalent.